Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 plus regorafenib or fruquintinib as third-line therapy for advanced colorectal cancer
ChiCTR2500110556Phase 4Not yet recruiting
- Sponsor
- Yantai Yuhuangding Hospital
- Start
- Oct 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of QL1706, regorafenib and fruquintinib in colorectal cancer (CRC), sponsored by Yantai Yuhuangding Hospital. Primary endpoint: Progression-free survival. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
QL1706regorafenibfruquintinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2500110556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110556.